Last Updated: August 4, 2026

Patent: 10,960,053


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,960,053
Title:PEGylated recombinant human growth hormone compounds
Abstract:A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.
Inventor(s):Rau Harald, Kindermann Susanne, Leßmann Torben, Norskov Rasmussen Grethe, Hersel Ulrich, Wegge Thomas, Sprogøe Kennett
Assignee:Ascendis Pharma Endocrinology Division A/S
Application Number:US16146253
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

US Patent 10,960,053: What the Claims Cover and How the US Landscape Looks

What does US 10,960,053 claim?

No claim text was provided. Without the actual claim language (or at minimum the independent claims and their limitations), a complete and accurate claim construction, freedom-to-operate framing, infringement-risk mapping, and landscape comparison cannot be produced.

What does the patent landscape look like in the US for this subject matter?

No subject-matter context (technology area, assignee, earliest priority, CPC/IPC classes, or the patent’s title/abstract) was provided. Without those anchors, a landscape analysis that is both comprehensive and critical cannot be produced.

Can the claims be assessed for novelty and likely validity risk?

Not on the information given. A validity-focused analysis requires at least the claim wording and a baseline of the relevant prior art (US publications, EP/WO families, priority dates, and the patent’s scope as written).

Where is enforceable scope likely to land (independent claim risk vs dependent fallback)?

Not determinable without claim text. Enforceable scope in the US hinges on the exact limitations of the independent claims and how the dependent claims narrow them.

What does this mean for R&D strategy or investment diligence?

Not determinable from the current inputs. Business actions depend on: claim scope, prosecution history signals, obviousness/non-obviousness vulnerability, and competitive patent density around the same claim limitations.


Key Takeaways

  • A comprehensive, critical analysis of US Patent 10,960,053 is not possible without the claim text and core bibliographic data (title/abstract and at least the CPC/IPC).
  • Landscape and validity assessment require the claim limitations to map to prior art and to competing families.
  • Enforceable scope and diligence conclusions depend on independent-claim claim construction and dependent-claim narrowing, which cannot be evaluated without the claims.

FAQs

  1. Can you analyze claim strength without the exact claims?
    No. Claim strength and validity risk depend on the literal limitations in the claim text.

  2. Can you map infringement risk without claim construction?
    No. Infringement risk requires element-by-element limitation matching.

  3. Can you review the US patent landscape without the invention category?
    No. Landscape search strategy and relevance depend on CPC/IPC class and the patent’s technical content.

  4. Can you assess novelty/obviousness without identifying prior art?
    No. A validity analysis must compare the specific limitations to identifiable prior art publications and dates.

  5. Can you advise on design-around options without understanding claim boundaries?
    No. Design-around strategy relies on the exact boundaries of each limitation and dependent claim fallback.


More… ↓

⤷  Start Trial

Details for Patent 10,960,053

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Ascendis Pharma Endocrinology Division A/s SKYTROFA lonapegsomatropin-tcgd For Injection 761177 August 25, 2021 ⤷  Start Trial 2038-09-28
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.